211 related articles for article (PubMed ID: 34992394)
1. New β-Lactam Antibiotics and Ceragenins - A Study to Assess Their Potential in Treatment of Infections Caused by Multidrug-Resistant Strains of
Paprocka P; Durnaś B; Mańkowska A; Skłodowski K; Król G; Zakrzewska M; Czarnowski M; Kot P; Fortunka K; Góźdź S; Savage PB; Bucki R
Infect Drug Resist; 2021; 14():5681-5698. PubMed ID: 34992394
[TBL] [Abstract][Full Text] [Related]
2. Antibacterial and Antibiofilm Activities of Ceragenins against
Bozkurt Güzel Ç; Hacioğlu M; Inci G; Savage PB
Turk J Pharm Sci; 2019 Dec; 16(4):444-449. PubMed ID: 32454748
[TBL] [Abstract][Full Text] [Related]
3. CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates.
Vila-Farrés X; Callarisa AE; Gu X; Savage PB; Giralt E; Vila J
Int J Antimicrob Agents; 2015 Nov; 46(5):568-71. PubMed ID: 26395218
[TBL] [Abstract][Full Text] [Related]
4. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Ceragenins Alone and in Combinations with Antibiotics Against Multidrug-Resistant Gram Negative Pathogens from Bloodstream Infections.
Yilmaz FN; Öksüz L; Demir ES; Döşler S; Savage PB; Güzel ÇB
Curr Microbiol; 2023 Aug; 80(10):327. PubMed ID: 37620557
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
Mirza HC; Hortaç E; Koçak AA; Demirkaya MH; Yayla B; Güçlü AÜ; Başustaoğlu A
J Glob Antimicrob Resist; 2020 Mar; 20():334-338. PubMed ID: 31568882
[TBL] [Abstract][Full Text] [Related]
9. In vitro assessment of CSA-131 and CSA-131 poloxamer form for the treatment of Stenotrophomonas maltophilia infections in cystic fibrosis.
Oyardi Ö; Savage PB; Erturan Z; Bozkurt-Guzel C
J Antimicrob Chemother; 2021 Jan; 76(2):443-450. PubMed ID: 33094334
[TBL] [Abstract][Full Text] [Related]
10. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Grupper M; Sutherland C; Nicolau DP
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
[TBL] [Abstract][Full Text] [Related]
11. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
[No Abstract] [Full Text] [Related]
12. Comparative In Vitro Activities of First and Second-Generation Ceragenins Alone and in Combination with Antibiotics Against Multidrug-Resistant
Ozbek-Celik B; Damar-Celik D; Mataraci-Kara E; Bozkurt-Guzel C; Savage PB
Antibiotics (Basel); 2019 Aug; 8(3):. PubMed ID: 31461867
[TBL] [Abstract][Full Text] [Related]
13. Core-shell magnetic nanoparticles display synergistic antibacterial effects against
Niemirowicz K; Piktel E; Wilczewska AZ; Markiewicz KH; Durnaś B; Wątek M; Puszkarz I; Wróblewska M; Niklińska W; Savage PB; Bucki R
Int J Nanomedicine; 2016; 11():5443-5455. PubMed ID: 27799768
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of cephalosporin-beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant
Alnimr AM; Alamri AM
J Taibah Univ Med Sci; 2020 Jun; 15(3):203-210. PubMed ID: 32647515
[TBL] [Abstract][Full Text] [Related]
15. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Henderson A; Tan E; McCarthy KL; Paterson DL
Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
[TBL] [Abstract][Full Text] [Related]
16. Ceragenins and Ceragenin-Based Core-Shell Nanosystems as New Antibacterial Agents against Gram-Negative Rods Causing Nosocomial Infections.
Karasiński M; Wnorowska U; Durnaś B; Król G; Daniluk T; Skłodowski K; Głuszek K; Piktel E; Okła S; Bucki R
Pathogens; 2023 Nov; 12(11):. PubMed ID: 38003809
[TBL] [Abstract][Full Text] [Related]
17.
Lomovskaya O; Rubio-Aparicio D; Nelson K; Sun D; Tsivkovski R; Castanheira M; Lindley J; Loutit J; Dudley M
Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782010
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
19.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro antimicrobial activities of CSA-142 and CSA-192, second-generation ceragenins, with CSA-13 against various microorganisms.
Bozkurt Guzel C; Oyardi O; B Savage P
J Chemother; 2018; 30(6-8):332-337. PubMed ID: 30663553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
